Who is sponsoring NCT05755243?

NCT05755243 is sponsored by Corporacion Parc Tauli.

What drugs are being tested in NCT05755243?

Interventions in NCT05755243: glucose sensor.

What condition does NCT05755243 study?

NCT05755243 studies Inflammatory Response to Glucose Sensors.

Is NCT05755243 still recruiting?

NCT05755243 is currently completed. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT05755243: TISSUESENSOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human Subcutaneous Inflammatory Response to Glucose Sensors

Completed Last updated 28 September 2023

What this trial tests

trial testing glucose sensor in Inflammatory Response to Glucose Sensors in 24 participants. Completed in 20 September 2023.

Timeline

21 June 2022

Primary endpoint
12 July 2023

20 September 2023

Quick facts

Lead sponsor	Corporacion Parc Tauli
Status	Completed
Study type	OBSERVATIONAL
Enrollment	24
Start date	21 June 2022
Primary completion	12 July 2023
Estimated completion	20 September 2023
Sites	1 location across Spain

Drugs / interventions tested

glucose sensor

Conditions studied

Inflammatory Response to Glucose Sensors — all drugs for Inflammatory Response to Glucose Sensors →

Sponsor

Corporacion Parc Tauli — full company profile →

Who can join

18 and older, any sex, with Inflammatory Response to Glucose Sensors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to describe the inflammatory response to enzimatic glucose sensors after 10 days of use and to evaluate the relationship between the magnitude of the FBR (foreign body response) with the accuracy of the sensor (MARD)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Corporacion Parc Tauli trials

Trials by the same sponsor.

NCT07331805 — Conservative Management in Primary Spontaneous Pneumothorax: a Multicenter Randomized Non-inferiority Study · NA · not yet recruiting
NCT06873360 — Medical Device for Oxaliplatin-Induced Neuropathy in Gastrointestinal Cancer Patients · completed
NCT06900335 — Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact · completed
NCT06511700 — Implementation of the Intravitreal Injection Administered by Nurses · enrolling by invitation
NCT07298720 — Assessing Fluid-responsiveness Using Non-invasive Hybrid Diffuse Optics on Peripheral Muscle · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05755243 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Corporacion Parc Tauli
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05755243.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing